Similar articles

• Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.

  Manganiello V. Manganiello V. Int J Impot Res. 2004 Jun;16 Suppl 1:S1-3. doi: 10.1038/sj.ijir.3901206. Int J Impot Res. 2004. PMID: 15224126 No abstract available.
• Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".

  Eardley I. Eardley I. Eur Urol. 2006 Jul;50(1):31-3. doi: 10.1016/j.eururo.2005.12.005. Epub 2006 Jan 4. Eur Urol. 2006. PMID: 16517052 No abstract available.
• Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?

  Burnett AL. Burnett AL. Eur Urol. 2006 Jul;50(1):29-30. doi: 10.1016/j.eururo.2006.03.008. Epub 2006 Mar 20. Eur Urol. 2006. PMID: 16567036 No abstract available.
• Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.

  Shabsigh R, Seftel AD, Rosen RC, Porst H, Ahuja S, Deeley MC, Garcia CS, Giuliano F. Shabsigh R, et al. Urology. 2006 Oct;68(4):689-96. doi: 10.1016/j.urology.2006.05.009. Urology. 2006. PMID: 17070333 Review. No abstract available.
• Phosphodiesterase type 5 inhibithors in older males.

  Frajese GV, Pozzi F. Frajese GV, et al. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):112-5. J Endocrinol Invest. 2005. PMID: 16760638 Review.